Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study

To describe the experience of treatment with baricitinib (BARI) and/or tocilizumab (TCZ), in monotherapy or combined, in patients admitted for interstitial pneumonia secondary to COVID19, and for 30 days after discharge. Medical records of patients admitted with COVID19 and IP with PaO2/FiO2 70 años...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Reumatología clinica 2022-03, Vol.18 (3), p.150-156
Hauptverfasser:	Rosas, José, Liaño, Francisco Pasquau, Cantó, Mónica Llombart, Barea, José María Carrasco, Beser, Amparo Raga, Rabasa, José Tomás Algado, Adsuar, Francisco Martínez, Auli, Brian Vila, López, Isabel Fernández, Sainz, Ana María Garijo, Ramis, Pere Esquerdo, Pérez, Laura Ruiz, Rebollo, Mª Luisa Navarrete, Lorido, Raquel Hernández, Escolar, Laura Gómez
Format:	Artikel
Sprache:	eng
Schlagworte:	Baricitinib COVID-19 COVID19 ICU Interstitial pneumonia Neumonía intersticial Original Tocilizumab UCI
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	To describe the experience of treatment with baricitinib (BARI) and/or tocilizumab (TCZ), in monotherapy or combined, in patients admitted for interstitial pneumonia secondary to COVID19, and for 30 days after discharge. Medical records of patients admitted with COVID19 and IP with PaO2/FiO2 70 años); 11 (18%) de ellos en los primeros 15 días del ingreso y cuatro (7%) entre los días 16 y 30. Veintitrés (38%) pacientes recibieron BARI, 12 (52%) en monoterapia (Grupo 1), durante seis (DE: 2.6) días de promedio, ninguno de ellos in
ISSN:	1699-258X 2173-5743 1885-1398
DOI:	10.1016/j.reuma.2020.10.009